Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colon Inflammation Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
20
States / cities
Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis

NCT03014284
View directory record Official record
Conditions
Colon Cancer, Colitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Not applicable Interventional

Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease

NCT03266484
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Probiotic Mixture, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease

NCT04827368
View directory record Official record
Conditions
IBD, Crohn Disease, Ulcerative Colitis
Interventions
Breath Test
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

NCT00488774
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 1 mg per kg, Golimumab 2 mg per kg, Golimumab 4 mg per kg
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Orange, California • Roseville, California • Littleton, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

NCT00048347
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVONEX
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2010 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab, placebo for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
78
States / cities
Coronado, California • Irvine, California • La Jolla, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis

NCT00033943
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
deligoparin
Drug
Lead sponsor
Incara Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
33
States / cities
Anaheim, California • Orange, California • Lakewood, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:48 PM EDT
Recruiting Phase 2 Interventional

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Eltrekibart, Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT03844932
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
ST-0529
Drug
Lead sponsor
Sublimity Therapeutics Holdco Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Palm Springs, California • Largo, Florida • New Port Richey, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jul 22, 2026, 2:48 PM EDT
Withdrawn Phase 4 Interventional

Addition of Lactobacillus to Metronidazole in Treatment of CDAD

NCT00304863
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
Interventions
Lactobacillus GG
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lutikizumab, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
48
States / cities
Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

NCT00073021
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
54
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 22, 2026, 2:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

NCT05611671
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions
MORF-057, Placebo
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Sun City, Arizona • Lancaster, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 2:48 PM EDT
Recruiting Phase 3 Interventional

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332
View directory record Official record
Conditions
Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Enrolling by invitation Not applicable Interventional

Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

NCT06560021
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Biopsy strategy
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
1,642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 4 Interventional

Single-dose Linaclotide for Capsule Endoscopy Preparation

NCT02465385
View directory record Official record
Conditions
Crohn's, Ulcerative Colitis, Gastrointestinal Bleeding
Interventions
Linaclotide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

NCT00503243
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Delayed and extended release mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 22, 2026, 2:48 PM EDT
Not listed No phase listed Observational

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.

NCT04897282
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UCRI
Diagnostic Test
Lead sponsor
Glycominds, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 22, 2026, 2:48 PM EDT
Completed No phase listed Observational

Anti-TNF Therapy for Refractory Colitis in Hospitalized Children

NCT02799615
View directory record Official record
Conditions
Colitis, Ulcerative, Bowel Diseases, Inflammatory
Interventions
Infliximab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Atlanta, Georgia • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

NCT00713310
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 400 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Jul 22, 2026, 2:48 PM EDT
Not yet recruiting Not applicable Interventional

Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD

NCT07017959
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
LpD3.5 supplementation., Placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 22, 2026, 2:48 PM EDT